[1]
|
S. C. Piscitelli, A. Thibault, W. D. Figg, A. Tompkins, D. Headlee, R. Lieberman, D. Samid and C. E. Myers, “Disposition of Phenylbutyrate and Its Metabolites, Phenylacetate and Phenylacetylglutamine,” Journal of Clinical Pharmacology , Vol. 35, 1995, pp. 368-373.
|
[2]
|
S. R. Burzynski, “Treatments for Astrocytic Tumors in Children: Current and Emerging Strategies,” Paediatr Drugs, Vol. 8, No. 3, 2006, pp. 67-178.
|
[3]
|
S. R. Burzynski, “Recent Clinical Trials in Diffuse Intrinsic Brainstem Glioma,” Cancer Therapy, Vol. 5, No. 5, 2007, pp. 379-390.
|
[4]
|
X. Li, S. Parikh, Q. Shu, H. Jung, C. Chow, L. Perlaky, et al., “Phenylbutyrate and Phenylacetate Induce Differentiation and Inhibit Proliferation of Human Medulloblastoma Cells,” Clinical Cancer Research, Vol. 10, 2004, pp. 1150-1159. doi:10.1158/1078-0432.CCR-0747-3
|
[5]
|
T. Iannitti and B. Palmieri, “Clinical and Experimental Applications of Sodium Phenylbutyrate,” Drugs in Research and Development, Vol. 11, No. 3, 2011, pp. 227-249.
|
[6]
|
D. Samid, W. R. Hudgins, S. Shack, L. Liu, P. Prasanna and C. E. Myers, “Phenylacetate and Phenylbutyrate as Novel, Nontoxic Differentiation Inducers,” Advances in Experimental Medical Biology, Vol. 400, 1997, pp. 501-505.
|
[7]
|
D. Samid, Z. Ram and W. R. Hudgins, et al., “Selective Activity of Phenylacetate against Malignant Gliomas Resemblance to Fetal Brain Damage in Phenylketonuria,” Cancer Research, Vol. 54, No. 4, 1994, pp. 891-895.
|
[8]
|
W. R. Hudgins, S. Shack, C. E. Myers and D. Samid, “Cytostatic Activity of Phenylacetate and Derivatives against Tumor Cells; Correlation with Lipophilicity and Inhibition of Protein Prenylation,” Biochemical Pharmacology, Vol. 50, No. 8, 1995, pp. 1273-1279.
doi:10.1016/0006-2952(95)02013-3
|
[9]
|
A. Thibault, D. Samid and M. R. Cooper, “Phase I Study of Phenylacetate Administered Twice Daily to Patients with Cancer,” Cancer, Vol. 75, No. 12, 1995, pp. 2932-2938. doi:10.1002/1097-0142(19950615)75:12<2932::AID-CNCR2820751221>3.0.CO;2-P
|
[10]
|
M. Sandler, C. R. Ruthven, B. L. Goodwin, A. Lees and G. M. Stern, “Phenylacetic Acid in Human Body Fluids: High Correlation between Plasma and Cerebrospinal Fluid Concentration Values,” Journal of Neurological Neurosurgery and Psychiatry, Vol. 45, No. 4, 1982, pp. 366-368. doi:10.1136/jnnp.45.4.366
|
[11]
|
S. W. Brusilow, “Phenylacetylglutamine May Replace Urea as a Vehicle for Waste Nitrogen Excretion,” Pediatric Research, Vol. 29, No. 2, 1991, pp. 147-150.
doi:10.1203/00006450-199102000-00009
|
[12]
|
T. Fujii, A. M. Nakamura, G. Yokoyama, M. Yamaguchi, K. Tayama, K. Miwa, et al., “Arrest by Pkc Alpha and MAPK Pathway in SKBR-3 Breast Cancer Cells,” Oncology Reports, Vol. 14, No. 2, pp. 489-494.
|
[13]
|
H. Tsuda, A. Iemura, M. Sata, M. Uchida, K. Yamana and H. Hara, “Inhibitory Effect of Antineoplaston A10 and AS2-1 on Human Hepatocellular Carcinoma,” Kurume Medical Journal, Vol. 43, No. 2, 1996, pp. 137-147.
doi:10.2739/kurumemedj.43.137
|
[14]
|
X.-J. Qu, S.-X. Cui, Z.-G. Tian, X. Li, M.-H. Chen, W.-F. Xu, et al., “Induction of Apoptosis in Human Hepatocellular Carcinoma Cells by Synthetic Antineoplaston A10,” Anticancer Research, Vol. 27, No. 4B, 2007, pp. 2427-2431.
|
[15]
|
S. Loewe and M. Die, “Versuch Einer Allgemeinen Pharmakologie der Arzneikombinationen,” Journal of Molecular Medicine, Vol. 6, No. 23, 1927, pp. 1077-1085.
doi:10.1007/BF01890305
|
[16]
|
S. Loewe, “Problems on the Practice of the Quantitative Evaluation of Drug Combinations,” Arzneimittelforschung, Vol. 11, 1961, pp. 899-902.
|
[17]
|
R. J. Tallarida, “Drug synergism: Its Detection and Applications,” Journal of Pharmacological Experimental Therapy, Vol. 298, No. 3, 2001, pp. 865-872.
|
[18]
|
K. Seifert and S. L. Croft, “In Vitro and in Vivo Interactions between Miltefosine and Other Antileishmanial Drugs,” Antimicrobial Agents in Chemotherapy, Vol. 50, No. 1, 2006, pp. 73-79.
doi:10.1128/AAC.50.1.73-79.2006
|
[19]
|
A. Nishiyama, M. Matsui, S. Iwata, K. Hirota, H. Masutani and H. Nakamura, “Identification of Thioredoxin-Binding Protein-2/Vitamin D(3) Upregulated Protein 1 as a Negative Regulator of Thioredoxin Function and Expression,” Journal of Biological Chemistry, Vol. 274, No. 31, 1999, pp. 21645-21650.
doi:10.1074/jbc.274.31.21645
|
[20]
|
M. Saitoh, H. Nishitoh, M. Fujii, K. Takeda, K. Tobiume, Y. Sawada, et al., “Mammalian Thioredoxin Is a Direct Inhibitor of Apoptosis Signal-Regulating Kinase (ASK) 1,” The EMBO Journal, Vol. 17, No. 9, 1998, pp. 2596-2606. doi:10.1093/emboj/17.9.2596
|
[21]
|
P. A. Marks, “Thioredoxin in Cancer-Role of Histone Deacetylase Inhibitors,” Seminars in Cancer Biology, Vol. 16, No. 6, 2006, pp. 436-443.
doi:10.1016/j.semcancer.2006.09.005
|
[22]
|
Y. Hirose, M. S. Berger and R. O. Pieper, “Abrogation of the Chk1-Mediated G2 Checkpoint Pathway Potentiates Temozolomide-Induced Toxicity in a P53-Independent Manner in Human Glioblastoma Cells,” Cancer Research, Vol. 61, No. 15, 2001, pp. 5843-5849.
|
[23]
|
R. G. Shao, C. X. Cao and Y. Pommier, “Abrogation of Chk1-Mediated S/G2 Checkpoint by UCN-01 Enhances Ara-C-Induced Cytotoxicity in Human Colon Cancer Cells,” Acta Pharmacologica Sinica, Vol. 25, No. 6, 2004, pp. 756-762.
|
[24]
|
B. Furnari, N. Rhind and P. Russell, “Cdc25 Mitotic Inducer Targeted by Chk1 DNA Damage Checkpoint Kinase,” Science, Vol. 277, No. 5331, 1997, pp. 1495-1497.
doi:10.1126/science.277.5331.1495
|
[25]
|
M. Jung, “Inhibitors of Histone Deacetylase as New Anti-cancer Agents,” Current Medicinal Chemistry, Vol. 8, No. 12, 2001, pp. 1505-1511.
|
[26]
|
S. H. Han, J. H. Jeon, H. R. Ju, et al. “VDUP1 Upregulated by TGF-Beta1 and 1,25-Dihydorxyvitamin D3 Inhibits Tumor Cell Growth by Blocking Cell-Cycle Progression,” Oncogene, Vol. 22, No. 26, 2003, pp. 4035-4046. doi:10.1038/sj.onc.1206610
|
[27]
|
A. P. Gilmore, “Anoikis,” Cell Death and Differentiation, Vol. 12, No. 52, 2005, pp. 1473-1477.
doi:10.1038/sj.cdd.4401723
|
[28]
|
A. J. Valentijn, N. Zouq and A. P. Gilmore, “Anoikis,” Biochemical Society Transactions, Vol. 32, No. 3, 2004, pp. 421-425. doi:10.1042/BST0320421
|
[29]
|
B. B. Zhou, H. J. Anderson and M. Roberge, “Targeting DNA Checkpoint Kinases in Cancer Therapy,” Cancer Biology and Therapy, Vol. 2, No. 4, 2003, pp. 16-22.
|
[30]
|
Y. Sanchez, C. Wong, R. S. Thoma, R. Richman, Z. Wu, S. Elledge, et al., “Conservation of the Chk1 Checkpoint Pathway in Mammals: Linkage of DNA Damage to Cdk Regulation Through Cdc25,” Science, Vol. 277, No. 5331, 1997, pp. 1497-1501. doi:10.1126/science.277.5331.1497
|
[31]
|
Y. Sanchez, J. Bachant, H. Wang, F. Hu, D. Liu, M. Tetzlaff, et al., “Control of the DNA Damage Checkpoint by Chk1 and Rad53 Protein Kinases through Distinct Mechanisms,” Science, Vol. 286, No. 5442, 1999, pp. 1166-1171. doi:10.1126/science.286.5442.1166
|
[32]
|
V. L. Gabai, C. O’Callaghan-Sunol, L. Meng, M. Y. Sherman and J. Yaglom, “Triggering Senescence Programs Suppresses Chk1 Kinase and Sensitizes Cells to Genotoxic Stresses,” Cancer Research, Vol. 68, No. 6, 2008, pp. 1834-1842. doi:10.1158/0008-5472.CAN-07-5656
|
[33]
|
Y. Tang, W. Liu, J. Zhou, Q. Gao and J. Wu, “Apoptotic Sensitivity to Irradiation Increased after Transfection of Chk1 Antisense Chain to HL-60 Cell Line,” Journal of Huazhong University of Science and Technology Medical Science, Vol. 25, No. 5, 2005, pp. 513-515.
doi:10.1007/BF02896003
|